Biolife Solutions Inc (BLFS) Financial Statements
Industry: Electromedical & Electrotherapeutic Apparatus
In fiscal 2025, Biolife Solutions reported revenue of $96.2M, up 17.0% from $82.3M the year before. Net income was -$4.6M (a -4.8% net margin), or -$0.10 per diluted share. Gross margin was 64.6% and operating margin was -17.3%. Operating activities generated $20.1M of cash, leaving $10.6M of free cash flow. At fiscal year end, Biolife Solutions held $405.9M in total assets against $34.0M in total liabilities, including $33.0M of cash and equivalents.
Open the full interactive Biolife Solutions financials → Quarterly statements, key ratios, valuation history and price charts.
Biolife Solutions Key Stats
| Share Price | $38.61 |
|---|---|
| Market Cap | $1.90B |
| Revenue YoY Growth | +17.0% |
| 52-Week Range | $18.15 – $39.22 |
| Shares Outstanding | 48.9 million (basic, 2026 Q2) |
Biolife Solutions Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $48.1M | $119.2M | $161.8M | $143.3M | $82.3M | $96.2M |
| Cost of Goods Sold | $53.7M | $153.1M | $307.3M | $214.1M | $89.4M | $78.7M |
| Gross Profit | -$5.6M | -$33.9M | -$145.5M | -$70.8M | -$7.1M | $62.1M |
| Operating Income | -$5.6M | -$33.9M | -$145.5M | -$70.8M | -$7.1M | -$16.6M |
| Pre-Tax Income | -$597,000 | -$27.8M | -$144.8M | -$66.3M | -$11.4M | -$12.1M |
| Income Tax | -$3.3M | -$20.1M | -$5.0M | $169,000 | -$38,000 | $49,000 |
| Net Income | $2.7M | -$7.6M | -$139.8M | -$66.4M | -$20.2M | -$4.6M |
| Diluted EPS | -$0.03 | -$0.20 | -$3.29 | -$1.52 | -$0.44 | -$0.10 |
Biolife Solutions Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $28.1M | $18.8M | $27.5M | $28.5M |
| Net Income | $621,000 | $11.1M | $1.2M | $45.1M |
| Diluted EPS | $0.01 | $0.23 | $0.02 | $0.91 |
Biolife Solutions Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $90.4M | $69.9M | $19.4M | $35.4M | $95.4M | $33.0M |
| Current Assets | $114.7M | $125.9M | $138.5M | $120.6M | $148.8M | $136.6M |
| Total Assets | $234.8M | $554.1M | $450.2M | $412.7M | $399.5M | $405.9M |
| Current Liabilities | $15.6M | $40.4M | $44.6M | $42.2M | $32.7M | $23.0M |
| Total Long-Term Debt | $1.3M | $7.2M | $25.6M | $25.1M | $15.9M | $10.0M |
| Total Liabilities | $29.6M | $73.9M | $86.0M | $75.1M | $50.6M | $34.0M |
| Shareholders' Equity | $205.2M | $480.1M | $364.2M | $337.7M | $348.9M | $371.9M |
Biolife Solutions Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $6.6M | -$4.6M | -$8.5M | -$12.5M | $8.4M | $20.1M |
| Cash From Investing | -$24.7M | -$13.2M | -$58.1M | $17.8M | $58.3M | -$71.5M |
| Cash From Financing | $102.1M | -$2.8M | $16.3M | $10.6M | -$6.8M | -$10.9M |
| Free Cash Flow | $4.7M | -$13.0M | -$18.9M | -$18.9M | $5.2M | $10.6M |
Figures from Biolife Solutions' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Biolife Solutions financials page for every line item.
Biolife Solutions Company Profile
| Ticker | BLFS |
|---|---|
| Exchange | Nasdaq |
| Industry | Electromedical & Electrotherapeutic Apparatus |
| Headquarters | Bothell, Washington |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000834365 |
Frequently Asked Questions
What was Biolife Solutions' revenue in fiscal 2025?
Biolife Solutions (BLFS) reported revenue of $96.2M for fiscal 2025.
What is Biolife Solutions' annual revenue history?
Biolife Solutions' annual revenue by fiscal year: 2020: $48.1M; 2021: $119.2M; 2022: $161.8M; 2023: $143.3M; 2024: $82.3M; 2025: $96.2M.
What was Biolife Solutions' net income in fiscal 2025?
Biolife Solutions reported net income of -$4.6M for fiscal 2025.
What was Biolife Solutions' earnings per share (EPS) in fiscal 2025?
Biolife Solutions' diluted EPS was -$0.10 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Biolife Solutions generate in fiscal 2025?
Biolife Solutions generated $10.6M of free cash flow in fiscal 2025.
What was Biolife Solutions' revenue last quarter?
In its most recent reported quarter (2026 Q2), Biolife Solutions reported revenue of $28.5M.
How much debt does Biolife Solutions have?
Biolife Solutions reported $10.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Biolife Solutions are outstanding?
Biolife Solutions reported a weighted average of 48.9 million basic shares outstanding in 2026 Q2.
What is Biolife Solutions' market cap?
Based on its latest closing price, Biolife Solutions (BLFS) has a market capitalization of about $1.90B.
When does Biolife Solutions' fiscal year end?
Biolife Solutions' fiscal year end, as registered with the SEC, is December 31.
Where is Biolife Solutions headquartered?
Biolife Solutions lists its business address in Bothell, Washington in its SEC filings.